CohBar (CWBR) Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
October 13, 2021 9:00 AM EDTMENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that data from its CB4211 Phase 1a/1b clinical study have been selected for presentation during the late-breaking poster session at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting® 2021). This event will be held virtually on November 12 15, 2021.
The presentation will discuss further details from the Phase 1a/1b clinical study of CB4211 in... More
